Highlights IRLAB Therapeutics AB

Equities

IRLAB A

SE0012675361

Market Closed - Nasdaq Stockholm Other stock markets 09:30:00 27/06/2024 pm IST			5-day change	1st Jan Change
13 ^SEK	-4.06%		+5.69%	+73.33%

27/05	Sweden’s IRLAB Therapeutics Names New CEO	MT
27/05	IRLAB Therapeutics AB Announces CEO Changes, Effective from August 1, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IRLAB Therapeutics AB Administers the First Dose in A Phase I Clinical Trial with the Drug Candidate Irl757	22/05	CI
IRLAB Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
IRLAB Therapeutics AB and McQuade Center for Strategic Research and Development, LLC Enter into Development Collaboration for IRL757 as Novel Treatment for Apathy	07/05	CI
IRLAB Has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757	06/05	CI
IRLAB Therapeutics Receives Minutes from End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program for Mesdopetam	22/03	CI
IRLAB Therapeutics AB Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson's Disease Psychosis	19/03	CI
IRLAB Therapeutics AB Completes End-Of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam	22/02	CI
IRLAB Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	07/02	CI
IRLAB's Pioneering Phase IIb Study Withpirepemat - React-PD - Provides New Insights in Specific Parkinson's Patient Population and Enables a Data Driven Prediction of Study Timelines	06/02	CI
IRLAB Is Granted an End-Of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program	03/01	CI
IRLAB Therapeutics AB Receives Grant from the Michael J. Fox Foundation to Support Development of IRL 757 for the Treatment of Apathy	21/12	CI
IRLAB Therapeutics AB's Drug Candidate IRL757 Completes all Preclinical Studies and Development Work Necessary to Start Phase I	21/12	CI
IRLAB Therapeutics AB Submits Request for an End-Of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program	18/12	CI
Irlab Therapeutics Secures European Patent for Parkinson’s Disease Drug Candidate	12/12	MT
IRLAB Therapeutics AB Receives Additional Patent for Drug Candidate Pirepemat That Expands its Patent Protection	12/12	CI
IRLAB Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	25/23/25	CI
IRLAB Therapeutics AB Signs With Clintrex and ProPharma Group Phase III Regulatory US Consultants to Support Preparation for Mesdopetam?s end-of-Phase 2 Meeting with the US FDA	10/23/10	CI
IRLAB Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	30/23/30	CI
IRLAB Therapeutics AB Announces Further Information on Results from Mesdopetam?s Clinical Phase IIb Study in Parkinson?s Disease Levodopa-Induced Dyskinesias and Phase III Preparatory Phase I Studies Performed by Ipsen	21/23/21	CI
IRLAB Secures Full Ownership of the Mesdopetam Project and Continues Product Development	21/23/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights IRLAB Therapeutics AB

Equities

IRLAB A

SE0012675361

Highlights

Filters